Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids
The primary objective of this study is to demonstrate the superior efficacy versus placebo of OBE2109 alone and in combination with add-back therapy for the reduction of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
Uterine Fibroids|Heavy Menstrual Bleeding
DRUG: OBE2109|DRUG: Placebo to match OBE2109|DRUG: Placebo to match Add-back|DRUG: Add-back
Percentage of Responders based on menstrual blood loss (MBL) volume reduction at Week 24, Assessed using the alkaline hematin method, From baseline to Week 24
Time to reduced menstrual blood loss, Assessed using the alkaline hematin method, Up to Week 52|Amenorrhea, Assessed using the alkaline hematin method, Up to Week 52|Time to amenorrhea, Up to Week 52|Number of days of uterine bleeding for the last 28-day interval prior to Week 24, Assessed using the alkaline hematin method, last 28-day interval prior to Week 24|Number of days of uterine bleeding for each 28-day interval, Assessed using the alkaline hematin method, Up to Week 52
Bone Mineral Density (BMD), Assessed by dual-energy X-ray absorptiometry (DXA) scan, From baseline up to Week 76|Endometrial biopsy, Assessed by histology, From baseline up to Week 52|Adverse events, Frequency and severity of Treatment-Emergent Adverse Events, Up to Week 76
The study is a prospective, randomized, parallel group, double-blind, placebo-controlled phase 3 study investigating the efficacy and safety of OBE2109 alone and in combination with add-back therapy for the treatment of uterine fibroids.

Subjects will be randomized to one of 5 treatment groups in a 1:1:1:1:1 ratio.